We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bioprinting Studies How Cancer Cells Grow and Spread

By LabMedica International staff writers
Posted on 26 Feb 2019
Print article
Image: Researchers found that cells behave differently in this three-dimensional (3D) soft tissue environment than on two-dimensional (2D) plastic or glass surfaces (Photo courtesy of the University of Minnesota).
Image: Researchers found that cells behave differently in this three-dimensional (3D) soft tissue environment than on two-dimensional (2D) plastic or glass surfaces (Photo courtesy of the University of Minnesota).
Novel use of a three-dimensional (3D) bioprinting technique has created new ways to study how cancer cells grow and spread.

Investigators at the University of Minnesota (Minneapolis/St. Paul, USA) have developed three-dimensional bioprinting techniques that have been adapted to build tumor constructs via precise placement of living cells, functional biomaterials, and programmable release capsules.

Three-dimensional bioprinting combines cells, growth factors, and biomaterials to fabricate biomedical constructs that maximally imitate natural tissue characteristics. Generally, three-dimensional bioprinting utilizes the layer-by-layer method to deposit biological materials to create tissue-like structures. Emerging innovations include bioprinting of cells or extracellular matrix deposited into a three-dimensional gel layer by layer to produce the desired tissue or organ.

The technique described in the January 21, 2019, online edition of the journal Advanced Materials enabled the spatiotemporal control of signaling molecular gradients, thereby dynamically modulating cellular behaviors at a local level.

Vascularized tumor models were created to mimic key steps of cancer dissemination (invasion, intravasation, and angiogenesis), based on guided migration of tumor cells and endothelial cells in the context of stromal cells and growth factors. In addition, the investigators described the benefits of using these metastatic models for drug screening by evaluating the anticancer efficacy of immunotoxins.

“This model is more consistent with what the body is like,” said senior author Dr. Angela Panoskaltsis-Mortari, professor of pediatrics at the University of Minnesota, “and, therefore, studying the effects of drugs with human cells at this level makes the results more meaningful and predictive of what will happen in the body.”

Related Links:
University of Minnesota

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.